ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 580,03
-0,69%
Dow Jones
40 793,03
1,45%
DAX
18 518,03
-0,44%
Brent Oil
83,47
-1,03%
Bitcoin
64 488,89
-0,56%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
05/06/201415h07Business WireTeva to Present at the Goldman Sachs 35th Annual Global Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
03/06/201415h26Dow Jones NewsU.S. Hot Stocks: Hot Stocks to WatchNYSE:TEVATeva Pharmaceutical Industries Ltd.
03/06/201414h25Edgar (US Regulatory)Report of Foreign Issuer (6-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
03/06/201413h30Business WireTeva to Acquire Labrys Biologics, Inc.: Novel Migraine Prophylaxis Treatment Adds Significant New Dimension to Teva’s Growi...NYSE:TEVATeva Pharmaceutical Industries Ltd
02/06/201423h13Dow Jones NewsADR Shares End MixedNYSE:TEVATeva Pharmaceutical Industries Ltd
02/06/201420h24Edgar (US Regulatory)Specialized Disclosure Report (sd)NYSE:TEVATeva Pharmaceutical Industries Ltd
02/06/201415h43Business WireTeva Announces New Organizational Structure & Senior Leadership Changes, Enabling the Global Integration of the Company & Pos...NYSE:TEVATeva Pharmaceutical Industries Ltd
30/05/201415h15Business WireTeva Receives Favorable Court Decision Regarding Generic Celebrex® Capsules; Teva Should Receive Sole Exclusivity for Generi...NYSE:TEVATeva Pharmaceutical Industries Ltd
29/05/201414h00Business WireTeva to Present at the Jefferies 2014 Global Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
27/05/201420h50Business WireTeva Announces Favorable European Patent Office Ruling in COPAXONE® Patent ProceedingNYSE:TEVATeva Pharmaceutical Industries Ltd
23/05/201414h00Business WireTeva Received FDA Approval for QVAR® (beclomethasone dipropionate HFA) with Dose CounterNYSE:TEVATeva Pharmaceutical Industries Ltd
23/05/201408h30Business WireTeva & Active Biotech to Continue with the Development of Nerventra® (Laquinimod) for Multiple Sclerosis Following Confirmat...NYSE:TEVATeva Pharmaceutical Industries Ltd
15/05/201414h21Dow Jones NewsMylan Applauds Court's Dismissal of Teva's Suit Against FDANYSE:TEVATeva Pharmaceutical Industries Ltd
15/05/201414h00Business WireTeva to Present at the UBS Global Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
13/05/201414h30Business WireTeva Announces FDA Acceptance of sNDA Filing for Pediatric Indication for QNASL® (Beclomethasone Dipropionate) Nasal AerosolNYSE:TEVATeva Pharmaceutical Industries Ltd
09/05/201414h00Business WireTeva to Present at the Bank of America Merrill Lynch 2014 Health Care ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
08/05/201414h00Business WireTeva Announces COPAXONE® Recognized as “Brand of the Year” by Pharmaceutical Executive MagazineNYSE:TEVATeva Pharmaceutical Industries Ltd
05/05/201414h00Business WireFDA Approves Teva’s SYNRIBO® (Omacetaxine Mepesuccinate) for Injection for Home AdministrationNYSE:TEVATeva Pharmaceutical Industries Ltd
01/05/201421h19Edgar (US Regulatory)Amended Report of Foreign Issuer (6-k/a)NYSE:TEVATeva Pharmaceutical Industries Ltd
01/05/201413h00Business WireTeva Reports First Quarter 2014 ResultsNYSE:TEVATeva Pharmaceutical Industries Ltd
30/04/201421h00Business WireTeva Shares New Data on MS Therapies at 66th American Academy of Neurology (AAN) Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
30/04/201415h48Business WireTeva Issues Updated Conference Call Information for First Quarter 2014 Financial Results on May 1, 2014NYSE:TEVATeva Pharmaceutical Industries Ltd
30/04/201415h16Dow Jones NewsTeva's Extended-Release Hydrocodone Shows Positive Results in StudyNYSE:TEVATeva Pharmaceutical Industries Ltd
30/04/201414h00Business WireTeva Reports Positive Results from Pivotal Phase III Study to Evaluate Hydrocodone Bitartrate Extended-Release Tablets (CEP-3...NYSE:TEVATeva Pharmaceutical Industries Ltd
29/04/201412h34Business WireTeva Receives European Marketing Authorization for DuoResp Spiromax® for the Treatment of Asthma and COPDNYSE:TEVATeva Pharmaceutical Industries Ltd
28/04/201422h34Dow Jones NewsTeva, OncoGenex Prostate Cancer Therapy Misses Endpoint in StudyNYSE:TEVATeva Pharmaceutical Industries Ltd
28/04/201413h00Business WireTeva & OncoGenex Announce Top-Line Survival Results of Phase III SYNERGY Trial Evaluating Custirsen in Combination with First...NYSE:TEVATeva Pharmaceutical Industries Ltd
28/04/201403h00Business WireTeva and Takeda Agree to Commercialize Rasagiline for Parkinson’s Disease Treatment in JapanNYSE:TEVATeva Pharmaceutical Industries Ltd
24/04/201417h33Dow Jones NewsActavis Settles Celebrex Case With Pfizer -- UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
24/04/201415h47Business WirePride-HD Study Enrolling Patients Globally to Further Evaluate Pridopidine for the Symptomatic Treatment of Huntington’s Di...NYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

BIT
I10133
IT0005589699 20241220 38...
BIT
UB3562
UniCredit Bank
BIT
1DB1
Deutsche Boerse
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés